RhumbLine Advisers’s Context Therapeutics CNTX Stock Holding History

RhumbLine Advisers’s Portfolio CNTX Stock Details CNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$38.7K	Buy	+69,844	New	+$142K	﹤0.01%	3725

Other funds holding CNTX

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

RhumbLine Advisers's CNTX Position: Q2 2026 in Review

RhumbLine Advisers opened a new position in Context Therapeutics (CNTX) in Q2 2026: 69,844 shares worth $38.7K. The stake represents ﹤0.01% of the portfolio and ranks #3725 among its holdings.

79 funds tracked by Wall St. Rank hold CNTX as of Q2 2026.

RhumbLine Advisers held 69,844 shares of Context Therapeutics worth $38.7K as of Q2 2026.
Context Therapeutics was a new RhumbLine Advisers position in Q2 2026.
Context Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #3725 holding.
79 funds tracked by Wall St. Rank held Context Therapeutics as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.